Market Overview

UPDATE: Barrington Research Initiates LeMaitre Vascular at Outperform on Valuation, Stable Outlook

Related LMAT
50 Biggest Movers From Friday
45 Stocks Moving In Friday's Mid-Day Session

Barrington Research initiated coverage on LeMaitre Vascular (NASDAQ: LMAT) with an Outperform rating and a $7.50 price target.

Barrington Research commented, "We are initiating coverage of LMAT with an OUTPERFORM investment rating and a $7.50 price target based on our belief that LMAT has built a strong and sustainable business in the vascular surgery market and its valuation is very attractive. … With a strong surgical product portfolio, a knowledgeable and focused sales force, good relationships with a large percentage of vascular surgeons, LMAT is looking to leverage these market leadership positions by offering complementary products in larger, more competitive markets. LMAT has been an astute acquirer the past 15 years and we expect this strategy to continue."

LeMaitre Vascular closed at $5.98 on Thursday.

Latest Ratings for LMAT

Oct 2017Canaccord GenuityMaintainsHold
Oct 2017BenchmarkDowngradesBuyHold
Jul 2017Canaccord GenuityDowngradesBuyHold

View More Analyst Ratings for LMAT
View the Latest Analyst Ratings

Posted-In: Barrington ResearchAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (LMAT)

View Comments and Join the Discussion!